Exagen (XGN) | Financial Analysis & Statements
Exagen Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
16.6M
Gross Profit
9.2M
55.35%
Operating Income
-5.0M
-29.91%
Net Income
-4.7M
-28.10%
Balance Sheet Metrics
Total Assets
58.0M
Total Liabilities
40.6M
Shareholders Equity
17.4M
Debt to Equity
2.33
Cash Flow Metrics
Operating Cash Flow
-1.8M
Free Cash Flow
-3.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Exagen Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 66.6M | 55.6M | 52.5M | 45.6M | 48.3M |
| Cost of Goods Sold | 27.8M | 22.5M | 23.1M | 24.2M | 20.6M |
| Gross Profit | 38.8M | 33.1M | 29.5M | 21.3M | 27.7M |
| Gross Margin % | 58.3% | 59.5% | 56.1% | 46.9% | 57.4% |
| Operating Expenses | |||||
| Research & Development | 6.3M | 5.4M | 4.9M | 9.9M | 7.2M |
| Selling, General & Administrative | 46.6M | 41.4M | 47.4M | 52.0M | 44.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 52.9M | 46.7M | 52.3M | 61.9M | 51.8M |
| Operating Income | -14.1M | -13.6M | -22.8M | -40.5M | -24.1M |
| Operating Margin % | -21.1% | -24.5% | -43.5% | -89.0% | -49.8% |
| Non-Operating Items | |||||
| Interest Income | 289.0K | 767.0K | 1.5M | 830.0K | 16.0K |
| Interest Expense | 4.3M | 2.2M | 2.3M | 2.4M | 2.6M |
| Other Non-Operating Income | -1.8M | - | - | -5.5M | 16.0K |
| Pre-tax Income | -19.9M | -15.1M | -23.7M | -47.7M | -26.7M |
| Income Tax | 51.0K | 12.0K | 33.0K | -282.0K | 175.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -20.0M | -15.1M | -23.7M | -47.4M | -26.9M |
| Net Margin % | -30.0% | -27.2% | -45.1% | -104.0% | -55.6% |
| Key Metrics | |||||
| EBITDA | -11.7M | -11.1M | -19.2M | -38.2M | -23.1M |
| EPS (Basic) | - | $-0.83 | $-1.34 | $-2.77 | $-1.68 |
| EPS (Diluted) | - | $-0.83 | $-1.34 | $-2.77 | $-1.68 |
| Basic Shares Outstanding | - | 18203044 | 17679467 | 17082348 | 15972256 |
| Diluted Shares Outstanding | - | 18203044 | 17679467 | 17082348 | 15972256 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Exagen Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 32.2M | 22.0M | 36.5M | 62.4M | 99.4M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 10.9M | 7.8M | 6.6M | 6.1M | 9.7M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 38.0K | 859.0K | 31.0K | 236.0K | 490.0K |
| Total Current Assets | 48.9M | 36.5M | 47.8M | 72.6M | 112.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 9.7M | 6.6M | 8.6M | 10.0M | 4.4M |
| Goodwill | - | - | - | 0 | 11.0M |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 756.0K | 550.0K | 616.0K | 528.0K | 433.0K |
| Total Non-Current Assets | 9.1M | 8.2M | 9.1M | 13.6M | 10.7M |
| Total Assets | 58.0M | 44.7M | 56.9M | 86.2M | 123.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.2M | 4.1M | 3.1M | 3.0M | 2.5M |
| Short-term Debt | 3.0M | 1.5M | 1.7M | 1.9M | 587.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | 302.0K | 445.0K | - |
| Total Current Liabilities | 14.2M | 13.5M | 11.9M | 9.6M | 9.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 22.7M | 21.5M | 22.0M | 33.3M | 27.5M |
| Deferred Tax Liabilities | - | - | - | 0 | 306.0K |
| Other Non-Current Liabilities | 2.0M | 157.0K | 357.0K | 867.0K | 1.4M |
| Total Non-Current Liabilities | 26.4M | 21.6M | 22.3M | 34.1M | 29.2M |
| Total Liabilities | 40.6M | 35.1M | 34.2M | 43.8M | 38.5M |
| Equity | |||||
| Common Stock | 23.0K | 18.0K | 17.0K | 17.0K | 16.0K |
| Retained Earnings | -314.3M | -294.3M | -279.2M | -255.5M | -208.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 17.4M | 9.5M | 22.7M | 42.5M | 84.9M |
| Key Metrics | |||||
| Total Debt | 25.7M | 23.0M | 23.7M | 35.2M | 28.1M |
| Working Capital | 34.7M | 22.9M | 35.9M | 63.0M | 103.4M |
Balance Sheet Composition
Exagen Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -20.0M | -15.1M | -23.7M | -47.4M | -26.9M |
| Depreciation & Amortization | 2.1M | 1.7M | 2.2M | 1.6M | 948.0K |
| Stock-Based Compensation | 2.2M | 1.8M | 3.6M | 4.7M | 4.7M |
| Working Capital Changes | -3.3M | -1.9M | -1.5M | 3.6M | -1.6M |
| Operating Cash Flow | -16.8M | -12.2M | -16.5M | -36.1M | -21.8M |
| Investing Activities | |||||
| Capital Expenditures | -626.0K | -515.0K | -804.0K | -4.3M | -2.4M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -626.0K | -515.0K | -804.0K | -4.3M | -2.4M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 23.7M | - | - | - | 0 |
| Debt Repayment | -20.8M | -861.0K | -10.9M | -696.0K | -525.0K |
| Financing Cash Flow | 24.0M | -861.0K | -10.9M | -935.0K | 64.2M |
| Free Cash Flow | -14.3M | -13.8M | -15.3M | -36.5M | -22.6M |
| Net Change in Cash | 6.6M | -13.6M | -28.2M | -41.4M | 40.0M |
Cash Flow Trend
Exagen Key Financial Ratios
Valuation Ratios
Forward P/E
-5.96
Price to Book
3.52
Price to Sales
0.97
PEG Ratio
-5.96
Profitability Ratios
Profit Margin
-29.97%
Operating Margin
-29.91%
Return on Equity
-147.85%
Return on Assets
-17.12%
Financial Health
Current Ratio
3.45
Debt to Equity
158.55
Beta
1.94
Per Share Data
EPS (TTM)
$-0.93
Book Value per Share
$0.76
Revenue per Share
$3.09
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| XGN | 64.5M | - | 3.52 | -147.85% | -29.97% | 158.55 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Burning Rock Biotech | 221.7M | -0.61 | 2.76 | -9.92% | -10.26% | 8.06 |
| Fonar | 118.6M | 16.35 | 0.70 | 6.01% | 7.13% | 24.44 |
| Biodesix | 107.5M | - | -34.62 | -383.09% | -39.85% | -30.44 |
Financial data is updated regularly. All figures are in the company's reporting currency.





